An observational study in Microvascular Disease, Microvascular Complications and Dementia, sponsored by University Hospital Bispebjerg and Frederiksberg. Active, not recruiting at 1 site in Denmark. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by University Hospital Bispebjerg and Frederiksberg · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Dementia with a site in Denmark — 6 open to participants now, 12 under way, 1 of them phase 3. Dementia · Denmark.
Among the 30 studies in Dementia with a site in Denmark, this one is one of 6 that started in 2025, is one of 9 observational ones, reaches primary completion later than 7 of the 11 other live ones, and was the 21st registered.
2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.
Browse Dementia studies →6 of the 30 studies in Dementia with a site in Denmark are open now. Recruiting first, the newest first:
Aarhus University Hospital · Sites in Denmark, Germany, Norway and 2 more countries
Ages 50+
University of Southern Denmark · Sites in Denmark
Ages 65+
Aarhus University Hospital · Sites in Denmark
Ages 60+
Zealand University Hospital · Sites in Denmark
Ages 50+ · Healthy volunteers
Center for Clinical Research and Prevention · Sites in Denmark
Ages 18+ · Healthy volunteers
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 5 · Phase 4 2
First in 2003; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 72 is below the median of 252 across 554 observational studies indexed under Dementia.
Median enrollment 339 across the 21 interventional studies, 140 across the 9 observational. Of the 17 that completed or were terminated, 5 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 30 have an industry lead sponsor. The 10 most frequent:
University Hospital Bispebjerg and Frederiksberg is the lead sponsor of 70 studies on the registry; 17 are open to participants now.
University Hospital Bispebjerg and Frederiksberg has 3 studies filed under Dementia — fewer than ten, so there is no comparison to draw.
3 of the studies in Dementia with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06624267University Hospital Bispebjerg and FrederiksbergTest of Reproducibility of [15O]H20-PET Assessment of Brain Perfusion | 2027-01 |
| NCT06451692University of Southern DenmarkPrioritising Patient Medication Review: Hospitals Reaching Out | 2027-01-01 |
| NCT07741526Arctic TherapeuticsSafety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD) | 2027-04-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 30 studies in Dementia with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In the aging population, ischemic heart disease, stroke and dementia are increasingly prevalent. Diagnosis and treatment of the former two i.e., large-vessel coronary heart disease and endovascular thrombectomy of the brain in relation to stroke have improved significantly. Yet, the majority of elderly patients with ischemic heart disease do not have large-vessel heart disease and it seems that small vessel disease (SVD) may explain a large fraction of these cases as well as the cardiovascular morbidity in the elderly. Hence, the current development in diagnostics and treatments of ischemic heart disease does not address the most common subtype of ischemic disease seen in elderly patients.
It has been suggested that SVD is part of a multisystem disorder and several systematic reviews have addressed the hypothesis of a potential link between small vessel disease of the heart, brain, and kidneys. Cerebral SVD is prevalent in the aging population causing cognitive impairment, dementia, and an increased risk of stroke, and cerebral hypoperfusion is an acknowledged cause of vascular dementia and a possible cause of Alzheimer's disease. Further, cognitive impairment within multiple cognitive domains is highly prevalent in heart failure and is associated to an increased risk of dementia. The link between heart failure and dementia may be due to multisystem SVD, although a direct link between the two is possible.
Among other known risk factors such as age, hypertension, and female sex, diabetes is a major cause of SVD and is linked to coronary heart disease as well as cognitive impairment. The diagnosis of cerebral SVD relies on MRI detecting infarctions, haemorrhages, microbleeds and ischemic white matter changes, i.e. Fazekas score. In contrast, perfusion PET is used to image myocardial perfusion in patients with coronary SVD; and coronary SVD is recognized as a part of the pathophysiology in angina, coronary artery disease, and heart failure. Perfusion PET before and after adenosine-induced vasodilation allows for measuring, the myocardial flow reserve (MFR), i.e. perfusion capacity, which in the absence of regional perfusion defects, is a measure of coronary SVD. Prof. Eva Prescott have recently shown that reduced MFR obtained by 82Rb PET is a strong predictor of future microvascular events and all-cause mortality.
Exercise is well known to improve cognitive health but professor Carl-Johan Boraxbekk has shown that the effect on cognitive performance may be dependent on the initial cerebrovascular status, as patients with moderate to severe white matter changes did not improve after a 6 months physical activation intervention in contrast to patients with mild changes. Yet, it is possible to improve brain function in diabetic patients through either dietary or exercise interventions.
Systemic SVD is measured as cerebral SVD (reduced brain perfusion during acetazolamide-induced vasodilation) and coronary SVD (reduced heart perfusion during adenosine-induced vasodilation). The researchers anticipate that patients with type 2 dabetes have reduced perfusion capacity of the brain and heart correlating to reduced cognition and cardiorespiratory fitness (VO2-max).
The goal of this clinical trial is to compare baseline measurements relevant to microvascular disease between patients with diabetes and increased risk of microvascular disease with healthy age-matched control.
The researchers wish to examine if small vessel disease is a disease that affects several organs at once in the same individuals by examining it in the brain and heart in the same participants. The researchers will also test if cardiorespiratory conditioning (VO2-max), blood perfusion to the heart and brain and cognitive performance are correlated in patients with microvascular disease.
To adress these aims the researchers have defined the following assumptions that they will refute or confirm through this study:
Perfusion capacity of the brain and heart, the cardiorespiratory fitness level of the subjects and cognitive performance are directly linked.
48 patients with diabetes and 24 healthy age-matched controls will undergo baseline testing that include:
Afterwards the researchers will compare the results between the two groups and see if there is a correlation between VO2-max, blood perfusion to the heart and brain and cognitive performance.
Patients with type 2 diabetes with increased risk of microvascular disease.
Inclusion Criteria for the patients with type 2 diabetes:
Diabetes type II diagnose with one of the following:
Non-proliferative diabetic retinopathy
Exclusion Criteria or the patients with type 2 diabetes:
Moderate to high intensity training >1 times/week.
Inclusion Criteria for the healthy age-matched controls:
Exclusion Criteria for the healthy age-matched controls:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Baseline measurements of: * \[15O\]H2O PET of heart and brain * Blood sampling * Echocardiography * Brain MRI * Cognitive tests * Cardiorespiratory fitness test * Muscular function test
Diagnostic Test: PET
Baseline measurements of: * \[15O\]H2O PET of heart and brain * Blood sampling * Echocardiography * Brain MRI * Cognitive tests * Cardiorespiratory fitness test * Muscular function test
Diagnostic Test: PET
PET imaging will be performed with a Discovery 710 PET/CT scanner (GE Healthcare, Milwaukee, WI, USA). Four 5-minute PET recordings will be performed of each subject within a single scanning session of 70 min. Two consecutive 5-minute scans are conducted of the heart and brain in rest. \[15O\]H2O, is produced on-site (GENtrace, GE, Uppsala, Sweden), and 600 MBq \[15O\]H2O is intravenously injected by an automatic Hidex Radiowater Generator (Hidex, Turku, Finland). To induce heart vasodilation, adenosine is infused (140 g/kg/min) for 6 min and a scan of the heart is repeated. To induce brain vasodilation, 1 g of acetazolamide is infused over 5 min and 15 min later the brain is scanned. Myocardial perfusion is calculated using CarimasCE software version 1.3.1. (Turku, Finland). Cerebral perfusion is calculated using PMOD software (PMOD Technologies, Switzerland).
Also known as: MRI, VO2-max, cognitive testing
[15O]H2O PET assessment of the blood perfusion to the brain
We will use the scan to determine our primary outcome: Blood perfusion to the brain. Radioactive water (\[15O\]H2O) will be used as a PET-tracer since it follows the blood and is the gold standard tracer for PET-based blood perfusion measurements. We measure the blood perfusion of both the brain as the perfusion capacity, meaning the difference between blood perfusion to the organ at rest and the maximally possible perfusion. In the brain we use injection of diamox to stimualte maximal dilation of the cerebral arteries which corresponds to the maximally possible perfusion of the brain.
Time frame: From baseline testing to end of study, 6 months
[15O]H2O PET assessment of the blood perfusion of the heart
We will use the scan to determine our primary outcome: Blood perfusion to the heart. Radioactive water (\[15O\]H2O) will be used as a PET-tracer since it follows the blood and is the gold standard tracer for PET-based blood perfusion measurements. We measure the blood perfusion of both the heart as the perfusion capacity, meaning the difference between blood perfusion to the organ at rest and the maximally possible perfusion. In the heart we use injection of adenosin to stimualte maximal dilation of the coronary arteries which corresponds to the maximally possible perfusion of the heart.
Time frame: From baseline testing to end of study, 6 months
Cognitive performance (CANTAB)
Testing of a broad range of cognitive functions. The test is tablet based and one of the most \"investigator-independent\" cognitive tests available. The test takes around 45 minutes to perform.
Time frame: From baseline testing to end of study, 6 months
Cognitive Performance (SCIP-D)
Assessed via SCIP-D in order to evaluate a broad range of cognitive areas in around 15-20 minutes. Both groups will undergo both tests. The primary investigator will receive learning in how to carry out the SCIP-D correctly. SCIP-D is a more clinically relevant test that can be used in a clinical setting to identify patients with cognitive dysfunction.
Time frame: From baseline testing to end of study, 6 months
Cardiorespiratory fitness (VO2-max)
Will be assessed as the maximal or peak oxygen consumption (VO2-max or VO2-peak) during a cardiopulmonal exercise test (CPET).
Time frame: From baseline testing to end of study, 6 months
Plan to share: No — Have not gotten the necessary clearence
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Dec 2027, 29 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Nov 2024 → Jul 2025 and primary completion Jan 2027 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Bispebjerg and Frederiksberg